3B Blackbio Dx posts 47% revenue jump, raises dividend
Annual revenue hit ₹141.92 cr as the diagnostic kit business scaled up. The board is returning ₹5 per share.
— 1 earlier story on 3B Blackbio Dx Ltd. →What's new
- Annual revenue surged 47% to ₹141.92 cr; net profit grew 25.6% to ₹59.93 cr.
- The diagnostic-kit division drove growth, with revenue rising from ₹84.28 cr to ₹131.11 cr.
- Board recommended a final dividend of ₹5 per share (50% payout on face value).
Why this matters
The results confirm the top-line impact of the Coris Bioconcept acquisition, with the diagnostic division now accounting for 92% of total revenue. Profit growth lagged revenue growth, a gap the company attributed to one-time M&A advisory costs tied to that deal.
What we're watching
- Integration costs and margin trajectory post-acquisition.
- Whether the Belgian acquisition moves the needle beyond the first full year of consolidation.
- Execution of the ₹5 dividend payout; shareholder approval timeline.
The full read
3B Blackbio Dx's full-year results read like an acquisition playbook. Revenue jumped 47% to ₹141.92 cr. The driver was the diagnostic-kit business, which scaled to ₹131.11 cr from ₹84.28 cr after the Coris Bioconcept deal. That division is now 92% of the company. Profit grew a more modest 25.6% to ₹59.93 cr, with the gap blamed on one-time M&A advisory fees. The board is returning some cash: a final dividend of ₹5 per share, a 50% payout on face value. The results are clean. The open question is whether the acquisition's value creation can outpace its integration costs over the next two years.
Questions answered
- What drove the 47% revenue jump?
- The diagnostic-kit division's revenue rose from ₹84.28 cr to ₹131.11 cr. The company says this reflects the integration of its Coris Bioconcept acquisition.
- Why did profit growth lag revenue growth?
- Net profit grew 25.6% to ₹59.93 cr versus the 47% revenue increase. The filing cites one-time M&A advisory costs related to the Belgian acquisition as a factor.
- What is the dividend?
- The board recommended a final dividend of ₹5.00 per equity share, which is a 50% payout on the face value.
- How big is the diagnostic division now?
- At ₹131.11 cr, the diagnostic-kit business contributed 92% of the company's total ₹141.92 cr in annual revenue.
- What other corporate actions were taken?
- The board appointed M/s Ali Jain & Sharma as internal auditors for the 2026-27 financial year.
Story so far
All notes on 3BBLACKBIO →- 29 May 2026 · 5:25 PM IST 3B Blackbio Dx posts 47% revenue jump, raises dividend
- 1d ago 3B Blackbio Dx revenue jumps 47% on diagnostic kit surge